“Will My Baby Be OK?” A Qualitative Analysis of Pregnant Women’s Suboxone ® Online Forum Posts

Abstract

Background:

Intentional or accidental drug-overdose is a leading cause of mortality in U.S. women of child-bearing age. Opioid use during pregnancy is not only associated with maternal overdose, but with low birth weight at term and neonatal abstinence syndrome (NAS). Buprenorphine was approved as a medication for opioid use disorder (MOUD) in the United States in 2002 and is for many women, a preferred treatment option versus methadone. Buprenorphine is relatively safe during pregnancy and is associated with lower rates of NAS than methadone. Given the importance of MOUD during pregnancy, relatively little information exists regarding patients’ questions and concerns about buprenorphine treatment, including the psychological challenges they face.

Aims:

The purpose of the study was to describe the perinatal concerns of women with opioid use disorder who posted to an online suboxone forum.

Methods:

Qualitative descriptive design to analyze some 170 posts from mothers with OUD to an online Suboxone^® support forum over the period 2016–2021.

Results:

The analysis of the interview data revealed 4 important themes: (a) Stigma resulting in self-deprecation, low self-esteem, and low self-efficacy; (b) stigma from family members and loved ones; (c) stigma from the medical profession; and (d) stigma from the community at-large (social stigma).

Conclusions:

There is compelling evidence to emphasize the importance of open communication and support between medical personnel and patients to ensure optimal outcomes for mother and baby.

Keywords

Get full access to this article

View all access options for this article.

References

Andrilla

C. H. A.

Patterson

D. G.

Moore

T. E.

Coulthard

Larson

E. H.

(2020). Projected contributions of nurse practitioners and physician’s assistant to buprenorphine treatment services for opioid use disorder in rural areas. Medical Care Research and Review, 77(2), 208–216. https://doi.org/10.1177/1077558718793070

Braun

Clarke

(2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77–101.

Burr

(2015). Social constructionism. Routledge.

Caritis

S. N.

Bastian

J. R.

Zhang

Kalluri

English

England

Bobby

Venkataramanan

(2017). An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. American Journal of Obstetrics and Gynecology, 217(4), 459.E1–549.E6. https://doi.org/10.1016/j.ajog.2017.06.029

Gemmill

Kiang

M. V.

Alexander

M. J.

(2019). Trends in pregnancy-associated mortality involving opioids in the United States, 2007–2016. American Journal of Obstetrics & Gynecology, 220(1), 115–116. https://doi.org/10.1016/j.ajog.2018.09.028

Goffman

(2009). Stigma: Notes on the management of spoiled identity. Simon & Schuster.

Graneheim

U. H.

Lundman

(2004). Qualitative content analysis in nursing research: Concepts, procedures and measures to achieve trustworthiness. Nurse Education Today, 24(2), 105–112. https://doi.org/10.1016/j.nedt.2003.10.001

Grossman

M. R.

Berkwitt

A. K.

Osborn

R. R.

Esserman

D. A.

Shapiro

E. D.

Bizzarro

M. J.

(2017). An initiative to improve the quality of care of infants with neonatal abstinence syndrome. Pediatrics, 139(6), Article e20163360. https://doi.org/10.1542/peds.2016-3360

Gupta

Khan

Kumar

(2022). Social media use by patients in health care: A scoping review. International Journal of Healthcare Management, 15(2), 121–131. https://doi.org/10/10080/20478799.2020.1860563

10.

Haight

S. C.

J. Y.

Tong

V. T.

Bohm

M. K.

Callaghan

W. M.

(2018). Opioid use disorder documented at delivery hospitalization—United States, 1999–2014. Morbidity and Mortality Weekly Report, 67(31), 845–849. https://doi.org/10.15585/mmwr.mm6731a1

11.

Jones

H. E.

Dengler

Garrison

O’Grady

K. E.

Seashore

Horton

Andringa

Jansson

L. M.

Thorp

(2014). Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence, 134, 414–417. https://doi.org/10.1016/j.drugalcdep.2013.11.006

12.

Jones

H. E.

Finnegan

L. P.

Kaltenbach

(2012). Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs, 72(6), 747–757. https://doi.org/10.2165/11632820-000000000-00000

13.

J. Y.

D’Angelo

D. V.

Haight

S. C.

Morrow

Cox

von Essen

B. S.

Strahan

A. E.

Harrison

Tevendale

H. D.

Warner

(2020). Vital signs: Prescription opioid pain reliever use during pregnancy—34 US jurisdictions, 2019. Morbidity and Mortality Weekly Report, 69(28), 897–903. https://doi.org/10.15585/mmwr.mm6928a1

14.

Krans

E. E.

Kim

J. Y.

Chen

Rothenberger

S. D.

James

A. E.

Kelley

Jarlenski

M. P.

(2021). Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction, 116(12), 3504–3514. https://doi.org/10.1111/add.15582

15.

Link

B. G.

Phelan

J. C.

(2001). Conceptualizing stigma. Annual Review of Sociology, 27(1), 363–385.

16.

Link

H. M.

Jones

Miller

Kaltenbach

Seligman

(2020). Buprenorphine-naloxone use in pregnancy: A systematic review and metaanalysis. American Journal of Obstetrics & Gynecology MFM, 2(3), Article 100179. https://doi.org/10.1016/j.ajogmf.2020.100179

17.

Naslund

J. A.

Bondre

Torous

Aschbrenner

K. A.

(2020). Social media and mental health: Benefits, risks, and opportunities for research and practice. Journal of Technology in Behavioral Science, 5(3), 245–257.

18.

Smid

M. C.

Schauberger

C. W.

Terplan

Wright

T. E.

(2020). Early lessons from maternal mortality review committees on drug-related deaths—time for obstetrical providers to take the lead in addressing addiction. American Journal of Obstetrics & Gynecology MFM, 2(4), Article 100177. https://doi.org/10.1016/j.ajogmf.2020.100177

19.

Speziale

H. S.

Streubert

H. J.

Carpenter

D. R.

(2011). Qualitative research in nursing: Advancing the humanistic imperative. Lippincott Williams & Wilkins.

20.

Terplan

Laird

H. J.

Hand

D. J.

Wright

T. E.

Premkumar

Martin

C. E.

Meyer

M. C.

Jones

H. E.

Krans

E. E.

(2018). Opioid detoxification during pregnancy: A systematic review. Obstetrics and Gynecology, 131(5), 803–814. https://doi.org/10.1097/AOG.0000000000002562

21.

Tiako

M. J. N.

Culhane

South

Srinivas

S. K.

Meisel

Z. F.

(2020). Prevalence and geographic distribution of obstetrician-gynecologists who treat medicaid enrollees and are trained to prescribe buprenorphine. JAMA Network Open, 3(12), Article e2029043. https://doi.org/10.1001/jamanetworkopen.2020.29043

22.

Verklan

M. T.

(2019). Time for the Finnegan neonatal abstinence syndrome scoring tool to be retired? The Journal of Perinatal & Neonatal Nursing, 33(3), 276–277. https://doi.org/10.1097/JPN.0000000000000427

23.

Weber

Miskle

Lynch

Arndt

Acion

(2021). Substance use in pregnancy: Identifying stigma and improving care. Substance Abuse and Rehabilitation, 12, 105–121. https://doi.org/10.2147/SAR.S319180

24.

Whalen

B. L.

Holmes

A. V.

Blythe

(2019). Models of care for neonatal abstinence syndrome: What works? Seminars in Fetal and Neonatal Medicine, 24(2), 121–132. https://doi.org/10.1016/j.siny.2019.01.004

25.

Zhang

Bastian

J. R.

Zhao

Chen

Shaik

I. H.

Chaphekar

Caritis

S. N.

Venkataramanan

(2020). Pregnancy alters CYP-and UGT-mediated metabolism of buprenorphine. Therapeutic Drug Monitoring, 42(2), 264–270. https://doi.org/10.1097/FTD.0000000000000724